Search Results

Former U.S. President Biden's Prostate Cancer Progress: Has Received Radiation Therapy and Hormone Therapy

The health condition of former U.S. President Joe Biden has recently drawn renewed attention. In an interview video, his son Hunter Biden stated that after Biden was diagnosed with prostate cancer, the cancer cells had metastasized, spreading to the bones and other parts of the body, and described the process as extremely painful. According to relevant information, Biden, now 83 years old, disclosed in May 2025 that he had been diagnosed with an aggressive form of prostate cancer, with cancer cells confirmed to have spread to the bones at that time. In October, a Biden spokesperson announced that he was undergoing radiation therapy and hormone therapy. Radiation therapy is one of the common nuclear technology medical applications in tumor treatment, primarily using ionizing radiation on tumor tissue to...

2026-08-10

DuChemBio Completes Supply Chain for Prostate Cancer Radiopharmaceutical

DuChemBio, a Korean radiopharmaceutical company, announced on August 4 that it has completed the supply chain for ProstaSeek (active ingredient: 18F-plotupolastat), a radiopharmaceutical for prostate cancer diagnosis, in the Yeongnam and Honam regions. The drug targets prostate-specific membrane antigen (PSMA), and all tertiary general hospitals in both regions that perform PET-CT scans and provide prostate cancer diagnosis and treatment have been included in its supply scope. According to data from the National Cancer Registry of the Korean Ministry of Health and Welfare, new prostate cancer cases reached 22,640 in 2023, accounting for 7.8% of all cancer cases and ranking sixth in male cancer incidence; with the increasing adoption of PSMA-targeted therapy, the demand for precise diagnosis before prostate cancer treatment is also growing rapidly.

2026-08-04

US FDA Approves Pluvicto Expanded Indication for Treatment of PSMA-Positive Metastatic Hormone-Sensitive Prostate Cancer

On July 31, 2026, Novartis announced that the U.S. Food and Drug Administration (FDA) has approved Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) in combination with an androgen receptor pathway inhibitor (ARPI) for the treatment of patients with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naive/sensitive prostate cancer. This disease is commonly referred to as metastatic hormone-sensitive prostate cancer (mHSPC). The approval is based on results from the Phase III PSMAddition trial. The study showed that compared with standard of care alone, namely ARPI combined with androgen deprivation therapy (ADT), Pluvicto plus standard of care reduced the risk of disease progression or death by...

2026-08-03